BioSpace News Archive

Innovent Biologics and LG Chem Life Sciences announced that the two parties have entered into a strategic collaboration and license agreement regarding LG Chem’s Tigulixostat, a late-stage novel non-purine xanthine oxidase inhibitor for the chronic management of hyperuricemia in patients with gout disease.

Prothena Corporation plc announced that it priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of $56.50 per ordinary share, before the underwriting discount and estimated offering expenses.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company focused on the development of Aramchol and Amilo-5MER, announced that on December 13, 2022, it received a letter from The Nasdaq Stock Market LLC, notifying the Company that it is eligible for an additional 180 calendar day period, or until June 12, 2023, to regain compliance with the Nasdaq’s minimum $1 bid price per share requirement.

BIOASIS TECHNOLOGIES INC. is pleased to announce that it will be holding an investor call on Tuesday, December 20th, 2022 at 11:00am EST to discuss the recently announced merger with Midatech Pharma plc.